Sanbio Company Revises FY27 Forecast After Acougo Pricing Approval

SanBio Company Limited [4592.T]

TOKYO, May 13 (Pulse News Wire) – Sanbio Company Limited (4592.T) revised its fiscal year 2027 (ending January 31, 2027) consolidated earnings forecast following the approval of pricing for its Acougo injection by the Central Social Insurance Medical Council on Friday. The approved price for Acougo, which is used to treat chronic motor paralysis associated with traumatic brain injury, stands at [NUM_27] yen (including consumption tax).

Sales revenue for the fiscal year is expected to increase due to the adoption of this pricing, while operating costs remain low due to past research and development expenses being capitalized. Operating profit reflects the anticipated rise in sales revenue. Additionally, the company reported a positive foreign exchange gain related to loans made to its subsidiary denominated in foreign currencies, contributing to higher-than-expected ordinary income and net income attributable to parent shareholders.

The revised forecast shows increased projected revenues and profits compared to previous estimates. SanBio plans to gradually introduce Acougo through hospitals that participated in clinical trials, aiming for initial shipments in the second half of 2026. The company also intends to conduct necessary post-marketing clinical studies within the seven-year regulatory requirement period and expand its global presence, targeting conditions such as cerebral infarction beyond traumatic brain injuries.

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.